Milrinone During Living Donor Hepatectomy

Not Applicable

Completed

• Conditions: Hepatectomy
• Interventions: Drug: placebo; Drug: milrinone

• Registration Number: NCT00966745
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2009-08
• Study First Submitted: 2009-08-13
• Study First Submitted QC: 2009-08-26
• Last Update Submitted: 2009-08-26
• Study First Posted: 2009-08-27
• Last Update Posted: 2009-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Living liver donors

Exclusion Criteria

• Donors with concurrent cardiac, pulmonary, and urologic disease
• Hepatectomy performed laparoscopically

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	-
milrinone	milrinone	milrinone infusion

Primary Outcome Measures

Name	Time	Method
condition of surgical field	intraoperative period (from the start of surgery to end of living donor hepatectomy)

Secondary Outcome Measures

Name	Time	Method
the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively	intraoperative period (from the start of surgery to end of living donor hepatectomy)

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of